Connect with us
European Gaming Congress 2024

Artificial Intelligence

Diabetic Neuropathic Pain Market to Proliferate, Assesses DelveInsight | Key Companies Active in the Domain – AstraZeneca, Eli Lilly and Company, Eisai, Helixmith, Lexicon, NeurogesX, Centrexion, Pure Green Pharmaceuticals

Published

on

<!– Name:DistributionId Value:8830816 –> <!– Name:EnableQuoteCarouselOnPnr Value:True –> <!– Name:IcbCode Value: –> <!– Name:CustomerId Value:1204938 –> <!– Name:HasMediaSnippet Value:false –> <!– Name:AnalyticsTrackingId Value:1091dded-bf30-4615-a435-f645c2538b74 –>

New York, USA, May 04, 2023 (GLOBE NEWSWIRE) — Diabetic Neuropathic Pain Market to Proliferate, Assesses DelveInsight | Key Companies Active in the Domain – AstraZeneca, Eli Lilly and Company, Eisai, Helixmith, Lexicon, NeurogesX, Centrexion, Pure Green Pharmaceuticals

The increasing prevalence of diabetes patients, rise in screening for pain among diabetics, increase in the geriatric population, and launch of newly approved drugs is likely to fuel the growth of the diabetic neuropathic pain market size during the forecast period (2023–2032).

DelveInsight’s Diabetic Neuropathic Pain Market Insights report includes a comprehensive understanding of current treatment practices, diabetic neuropathic pain emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

Key Takeaways from the Diabetic Neuropathic Pain Market Report

Advertisement
Stake.com
  • As per DelveInsight analysis, the diabetic neuropathic pain market is expected to grow positively owing to several underline factors during the study period (2019–2032).
  • DelveInsight’s analysis shows that diabetic neuropathic pain cases show an increasing trend in the forecasted period in the 7MM. 
  • Leading diabetic neuropathic pain companies such as AstraZeneca, Centrexion Therapeutics, Aptinyx, Pure Green Pharmaceuticals Inc., Eli Lilly and Company, Regenacy Pharmaceuticals LLC, Helixmith Co., Ltd., Vertex Pharmaceuticals Incorporated, Eisai Inc., NeuroBo Pharmaceuticals Inc., Dong-A ST Co., Ltd., Daiichi Sankyo, Inc., NeurogesX, Lexicon Pharmaceuticals, and others are developing novel diabetic neuropathic pain drugs that can be available in the diabetic neuropathic pain market in the coming years.
  • Some of the key therapies for diabetic neuropathic pain treatment include MEDI 7352, CNTX6016, NYX2925, CBD/PEA, LY3857210, Ricolinostat, Engensis, VX-548, E2007, DA-9801, DS-5565, Capsaicin Dermal Patch, LY3526318, LX9211, and others.
  • Several diabetic neuropathic pain therapies are awaiting approval, while some therapies are in the advanced stages of development. 

Discover which therapies are expected to grab the major diabetic neuropathic pain market share @ Diabetic Neuropathic Pain Market Report

Diabetic Neuropathic Pain Overview

Diabetic neuropathic pain is a well-known diabetes consequence and the leading cause of all neuropathic pain. Diabetic neuropathic pain affects almost one-third of all diabetic patients. It is defined as the presence of signs and symptoms of nerve dysfunction in diabetic individuals after all other explanations have been ruled out. Prolonged high blood sugar levels can harm nerves throughout the body, but diabetic neuropathic pain most impact the legs and feet.

Diabetic neuropathic pain is characterized by tingling, burning, sharp, shooting, lancinating feelings, and electric shocks. It is usually classified as moderate to severe, and it is often worse at night, causing sleep disruption. The discomfort might be persistent and accompanied by cutaneous allodynia, which can significantly impact the patient’s quality of life, limiting their capacity to do everyday tasks and negatively impacting their mood. Pain may also be a cause of withdrawal from recreational and social activities, and it may be linked to depression.

Diabetic Neuropathic Pain Epidemiology Segmentation

The diabetic neuropathic pain epidemiology section provides insights into the historical and current diabetic neuropathic pain patient pool and forecasted trends for the seven individual major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders.

Advertisement
Stake.com

The diabetic neuropathic pain market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Diabetic Neuropathic Pain Prevalent Cases
  • Diabetic Neuropathic Pain Diagnosed and Treatable Cases
  • Diabetic Neuropathic Pain Gender-specific Cases  
  • Diabetic Neuropathic Pain Type-specific Cases  

Download the report to understand which factors are driving diabetic neuropathic pain epidemiology trends @ Diabetic Neuropathic Pain Epidemiological Insights

Diabetic Neuropathic Pain Treatment Market 

Current diabetic neuropathic pain treatment has two key goals: to target the underlying pathophysiological processes to avoid nerve fiber loss and reduce the unpleasant symptoms of PDN to normalize physical and psychological functioning. Tricyclic agents (TCAs), serotonin-norepinephrine reuptake inhibitors (SNRIs), or -aminobutyric acid (GABA) analogs (gabapentin or pregabalin) are commonly recommended as first-line medications, followed by opioids and topical therapies. Diabetic neuropathic pain is typically treated with TCAs, SNRIs, and GABA analogs. 

In September 2004, the SNRI duloxetine (Cymbalta, Eli Lilly) was licensed as the first medicine to treat the neuropathic pain associated with diabetic neuropathic pain. Duloxetine inhibits neuronal serotonin and norepinephrine reuptake. Although the specific mechanism of action of the drug’s central pain-inhibitory effect is unknown, it is thought to be connected to the potentiation of serotonergic and noradrenergic activity in the CNS. Blocking norepinephrine reuptake, in particular, has been shown to help with neuropathic pain.

Since the 1960s, traditional anticonvulsants have been utilized to treat neuropathy. However, in 2004, the FDA approved newer anticonvulsants, such as pregabalin, to treat DPN’s neuropathic pain. Because of its effectiveness in lowering pain and pain-related sleep disturbance, AAN guidelines recommend pregabalin as the first-line therapy for diabetic neuropathic pain treatment. Japan’s PMDA approved Mirogabalin for diabetic neuropathic pain treatment in 2019. Daiichi Sankyo is undertaking clinical research for Mirogabalin in the United States, with a planned launch within the study period. 

Advertisement
Stake.com

To know more about diabetic neuropathic pain treatment, visit @ Diabetic Neuropathic Pain Treatment Drugs 

Key Diabetic Neuropathic Pain Therapies and Companies

  • MEDI 7352: AstraZeneca
  • CNTX6016: Centrexion Therapeutics
  • NYX2925: Aptinyx
  • CBD/PEA: Pure Green Pharmaceuticals Inc.
  • LY3857210: Eli Lilly and Company
  • Ricolinostat: Regenacy Pharmaceuticals LLC
  • Engensis: Helixmith Co., Ltd.
  • VX-548: Vertex Pharmaceuticals Incorporated
  • E2007: Eisai Inc.
  • DA-9801: NeuroBo Pharmaceuticals Inc./Dong-A ST Co., Ltd.
  • DS-5565: Daiichi Sankyo, Inc.
  • Capsaicin Dermal Patch: NeurogesX
  • LY3526318: Eli Lilly and Company
  • LX9211: Lexicon Pharmaceuticals

Learn more about the FDA-approved drugs for diabetic neuropathic pain @ Drugs for Diabetic Neuropathic Pain Treatment 

Diabetic Neuropathic Pain Market Dynamics

The diabetic neuropathic pain market is expected to change in the coming years. One of the primary aspects recognized to influence the growth of the neuropathic pain market is the discovery of new medications for the treatment of neuropathic and chronic pains. Companies are focused on clinical studies to find therapies to treat diabetic neuropathic pain effectively. For example, Eli Lilly produced duloxetine (LY248686) for diabetic peripheral neuropathic pain (DPNP), while Daichi developed mirogabalin for DPNP. Another factor driving the expansion of the diabetic peripheral neuropathic pain market is the development of point-of-care diagnostics to identify and evaluate diabetic peripheral neuropathic pain. DPNCheck by NeuroMetrix, for example, is a rapid, accurate, and quantitative nerve conduction test used to examine nerves to detect, stage, and monitor neuropathy objectively. 

Moreover, the diabetic neuropathic pain pipeline is highly robust; many possible therapies are being studied for diabetic neuropathic pain treatment, and it is safe to assume that the therapeutic space will substantially impact the diabetic neuropathic pain market throughout the forecast period. Furthermore, the expected introduction of emerging therapies with improved efficacy, more awareness initiatives programs, and a further improvement in the diagnosis rate will likely boost the growth of the diabetic neuropathic pain market in the 7MM.

Advertisement
Stake.com

However, certain factors may affect the growth of the diabetic neuropathic pain market. The diabetic neuropathic pain market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the diabetic neuropathic pain market growth.

Report Metrics Details
Study Period 2019–2032
Coverage 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]
Base Year 2019
Key Diabetic Neuropathic Pain Companies AstraZeneca, Centrexion Therapeutics, Aptinyx, Pure Green Pharmaceuticals Inc., Eli Lilly and Company, Regenacy Pharmaceuticals LLC, Helixmith Co., Ltd., Vertex Pharmaceuticals Incorporated, Eisai Inc., NeuroBo Pharmaceuticals Inc., Dong-A ST Co., Ltd., Daiichi Sankyo, Inc., NeurogesX, Lexicon Pharmaceuticals, and others
Key Diabetic Neuropathic Pain Therapies MEDI 7352, CNTX6016, NYX2925, CBD/PEA, LY3857210, Ricolinostat, Engensis, VX-548, E2007, DA-9801, DS-5565, Capsaicin Dermal Patch, LY3526318, LX9211, and others

Scope of the Diabetic Neuropathic Pain Market Report

  • Therapeutic Assessment: Diabetic Neuropathic Pain current marketed and emerging therapies
  • Diabetic Neuropathic Pain Market Dynamics: Attribute Analysis of Emerging Diabetic Neuropathic Pain Drugs
  • Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
  • Unmet Needs, KOL’s views, Analyst’s views, Diabetic Neuropathic Pain Market Access and Reimbursement

Discover more about diabetic neuropathic pain drugs in development @ Diabetic Neuropathic Pain Clinical Trials

Table of Contents

1. Diabetic Neuropathic Pain Market Key Insights
2. Diabetic Neuropathic Pain Market Report Introduction
3. Diabetic Neuropathic Pain Market Overview at a Glance
4. Diabetic Neuropathic Pain Market Executive Summary
5. Disease Background and Overview
6. Diabetic Neuropathic Pain Treatment and Management
7. Diabetic Neuropathic Pain Epidemiology and Patient Population
8. Patient Journey
9. Diabetic Neuropathic Pain Marketed Drugs
10. Diabetic Neuropathic Pain Emerging Drugs
11. Seven Major Diabetic Neuropathic Pain Market Analysis
12. Diabetic Neuropathic Pain Market Outlook
13. Potential of Current and Emerging Therapies
14. KOL Views
15. Unmet Needs
16. SWOT Analysis
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

Related Reports

Diabetic Neuropathic Pain Pipeline

Advertisement
Stake.com

Diabetic Neuropathic Pain Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Diabetic Neuropathic Pain companies, including Clarity Pharmaceuticals Ltd, Eli Lilly and Company, Laboratorio Elea Phoenix S.A., PersonGen BioTherapeutics (Suzhou) Co., Ltd., among others.

Diabetic Neuropathy Market

Diabetic Neuropathy Market Insight, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key diabetic neuropathy companies, including Goldfinch Bio, Novartis, Serodus, CURACLE, Daiichi Sankyo, among others.

Diabetic Neuropathy Pipeline

Diabetic Neuropathy Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key diabetic neuropathy companies, including Goldfinch Bio, Novartis, Serodus, CURACLE, Daiichi Sankyo, among others.

Advertisement
Stake.com

Diabetic Peripheral Neuropathy Pipeline

Diabetic Peripheral Neuropathy Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key diabetic peripheral neuropathy companies, including CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Helixmith, Aptinyx, Lexicon Pharmaceuticals, Lateral Pharma Pty Ltd., SIMR (Australia) Biotech Pty Ltd., WinSanTor, Inc., among others.

Diabetes Market

Diabetes Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key diabetes companies, including TikoMed, Avotres, REMD Biotherapeutics, Novo Nordisk, among others.

Type 1 Diabetes Market

Advertisement
Stake.com

Type 1 Diabetes Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key type 1 diabetes companies, including Histogen, Novo Nordisk, Prevention Bio, among others.

Other Trending Reports

Treatment Resistant Depression Market | Advanced Renal Cell Carcinoma Market | Diabetic Neuropathic Pain Market | Centronuclear Myopathy Market | Head And Neck Squamous Cell Carcinoma Market | Acquired Immunodeficiency Syndrome Market | Acute Intermittent Porphyria Market | Neurovascular Devices Market | Defibrillators Market | Ventricular Hypertrophy Market | Urolithiasis Market | Alopecia Areata Market | Autonomic Dysfunction Market | Acute Ischemic Stroke Ais Market | Adenoid Cystic Carcinoma Market | Aspergillosis Market | Biliary Atresia Market | Biliary Tumor Market | Chronic Inducible Urticaria Market | Chronic Insomnia Market | Critical Limb Ischemia Market | Endometriosis Pain Market | Generalized Anxiety Disorder Gad Market | Hallux Valgus Market | Hemophilia B Market | Immunologic Deficiency Syndrome Market | Neuromodulation Devices Market | Neurovascular Thrombectomy Devices Market | Osteosarcoma Market | Pemphigus Vulgaris Market | Progressive Familial Intrahepatic Cholestasis Market | Pruritus Market | Radiation Toxicity Market | Pulmonary Hypertension Associated With Interstitial Lung Disease Market | Cluster Headaches Market | Foot And Ankle Devices Market | Intravenous Immunoglobulin Market | Bile Duct Neoplasm Market | Blood Glucose Monitoring Systems Market | Rett Syndrome Market | Tissue Heart Valves Market | Cardiac Biomarkers Testing Devices Market | Subscription Healthcare | Hepatorenal Syndrome Market | Central Venous Catheters Market | Continuous Renal Replacement Therapy Machines Market | Nonalcoholic Steatohepatitis Market | Necrotizing Enterocolitis Market | Cardiac Amyloidosis Market | Artificial Iris Market | Aortic Aneurysm Stent Grafts Market | Polypoidal Choroidal Vasculopathy Market | Adrenal Crisis Market | Hearing Implants Market | Image Guided Surgery Devices Market | Angioedema Market | Bladder Cancer Market

Related Healthcare Services

Healthcare Consulting

Advertisement
Stake.com

Healthcare Competitive Intelligence Services

Healthcare Asset Prioritization Services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Connect with us on LinkedIn|Facebook|Twitter

Advertisement
Stake.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Artificial Intelligence

ZA Tech Rebrands as Peak3, Raises US$35M Series A led by EQT

Published

on

za-tech-rebrands-as-peak3,-raises-us$35m-series-a-led-by-eqt

SINGAPORE, June 19, 2024 /PRNewswire/ — ZA Tech, the next-generation insurance core system SaaS provider, has rebranded as Peak3. With the successful completion of its US$35 million Series A fundraising from EQT (lead investor) and Alpha JWC Ventures, Peak3 now accelerates its expansion in the EMEA region and investments in complementary data and AI solutions.

In a market dominated by fragmented legacy technology, Peak3 has pioneered a cloud-native, modular insurance core and distribution system that combines comprehensive capabilities for life, health, and property and casualty (P&C) insurance. Since its founding in 2018, Peak3 has become a trusted technology partner to global insurers such as AIA, Generali, Prudential, and Zurich for their digital and traditional business. It has also partnered with leading digital platforms such as Carro, Grab, Klook, and PayPay to build and scale their embedded insurance businesses.
Besides the successful fundraising, Peak3 has recently achieved key milestones underpinning the rebranding. These transformative achievements include launching its first multi-country, multi-tenant core modernisation in Europe, rolling out an integrated customer data and big data platform for scaling analytics and AI capabilities, and establishing its first technology centre in Europe. The rebranding coincides with another major milestone: Issuing over a billion insurance policies on Peak3’s systems – including the first policies issued to North American customers and the first ones to be issued in Africa.
“We have evolved from an embedded insurance pioneer in Asia to a global end-to-end technology partner for the insurance industry,” said Bill Song, Peak3 Group CEO and Co-Founder. “Our new name represents three pinnacles: scaling the heights of innovation, surpassing performance limits, and delivering superior reliability – as we help insurers reach the highest summits of their cloud, data, and AI transformation.”
Bill Song also emphasised the growth opportunity: “There is an incredible tech investment backlog in the US$7-trillion global insurance industry. Continued digitalisation and the proliferation of AI will require structural investments by insurers over the next decade to modernise their core systems. We are uniquely positioned to capture this opportunity by providing the tech core foundations and innovation use cases.” 
To accelerate its growth journey, Peak3 completed its Series A fundraising and welcomed two new investors on its cap table: EQT, a major global technology investor with a deep heritage in Europe, and Alpha JWC Ventures, a leading venture firm in Southeast Asia. With the funding, Peak3 will advance its analytics and AI capabilities toward an intelligent core insurance solution, grow its EMEA operations and establish new system integrator partnerships. Peak3 targets double-digit ARR growth this year and is on the path to reach cashflow breakeven over the coming quarters.
“Peak3 has also proven its capability to deliver greenfield digital insurance initiatives and complex multi-country core modernisation projects in APAC and EMEA. As the lead investor, EQT is committed to empowering Peak3 in its go-to-market acceleration by leveraging our global network,” stated Clara Ho, Partner at EQT.
J.P. Morgan acted as exclusive financial advisor to Peak3 for this Series A fundraising.
For media inquiries and interview requests, please contact Carling Sia, Global Head of Branding and Marketing, at [email protected].
For more information on Peak3, please visit www.peak3.com. For more information on EQT, please visit www.eqtgroup.com.For more information on Alpha JWC Ventures, please visit www.alphajwc.com.
Photo – https://mma.prnewswire.com/media/2439599/Peak3_PR_Announcement_Photo__002.jpg

View original content:https://www.prnewswire.co.uk/news-releases/za-tech-rebrands-as-peak3-raises-us35m-series-a-led-by-eqt-302175431.html

Continue Reading

Artificial Intelligence

Lucinity Recognized as One of the Top 100 AI Fintech Companies Globally

Published

on

lucinity-recognized-as-one-of-the-top-100-ai-fintech-companies-globally

REYKJAVIK, Iceland, June 18, 2024 /PRNewswire/ — Lucinity has been featured in the AIFinTech100 list for 2024, marking its recognition as one of the top AI companies in the financial services industry. The AIFinTech100 list, curated by industry experts, highlights the most innovative fintech companies globally. Lucinity was selected from over 2,000 fintech firms for its problem-solving, market potential, innovation, and customer engagement. Earlier this year, Lucinity was also highlighted as a RegTech100 company.

 
 
This recognition comes amid rapid AI adoption in fintech. According to Fintech Global, research predicts the AI market in fintech will grow from $42.83 billion to $44.08 billion by 2024, reaching $50.87 billion by 2029. Banks alone are expected to spend $4.9 billion on AI platforms by 2024, with a 21.8% annual growth rate since 2019.
Lucinity’s inclusion in the AIFinTech100 list reflects its success in developing AI solutions that enhance efficiencies and cost savings for financial crime operations teams. Notably, Luci, the world’s first Generative AI copilot for financial crime investigations, launched in 2023, leverages Microsoft OpenAI technologies to augment human analysts’ capabilities, reducing investigation times from 3 hours to just 30 minutes. 
Lucinity also recently launched Luci as a copilot plugin at Money20/20. Financial institutions are now able to integrate Luci with any web-based enterprise application including CRM systems, Case Manager systems, and Excel, delivering immediate ROI with zero upfront integration. 
Security remains a significant challenge in AI adoption. Lucinity addresses this by partnering with Microsoft Azure develop a secure infrastructure. With a strong emphasis on compliance, Luci offers comprehensive auditability through its detailed Audit Log functionality.
Guðmundur Kristjánsson (GK), CEO of Lucinity, comments, “Being named in the AIFinTech100 showcases our impact amongst banks and fintech through advanced AI. It underscores our platform’s ability to empower compliance teams, deliver ROI, and reduce operational costs.”
Richard Sachar, Director of FinTech Global, added, “AI is revolutionizing financial services, increasing efficiencies and offering personalized products. This year’s AIFinTech100 list includes top innovators transforming the industry with AI applications.”
Lucinity’s inclusion in the AIFinTech100 list for 2024 follows several achievements, including winning the Microsoft Partner of the Year Awards for Sustainability and Social Impact and Partner of the Year – Iceland. Lucinity was also included in Chartis Research’s FinCrime and Compliance 50 Ranking for 2024 and was recognized as the best tool for Workflow Automation.
Name: Celina PabloEmail: [email protected] +354 792 4321
Logo – https://mma.prnewswire.com/media/2208676/4770157/Lucinity_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/lucinity-recognized-as-one-of-the-top-100-ai-fintech-companies-globally-302176061.html

Continue Reading

Artificial Intelligence

CRISIL wins Model Validation Tools and Accelerators category award, other recognitions from Chartis

Published

on

crisil-wins-model-validation-tools-and-accelerators-category-award,-other-recognitions-from-chartis

Recognized among top 50 financial services firms for analytics and risk tech
MUMBAI, India, June 18, 2024 /PRNewswire/ — CRISIL, a global provider of advanced analytics and risk management solutions, has won the Solution Category award for Model Validation Tools and Accelerators as part of the latest Chartis STORM 2024 report.

Published by Chartis Research, the leading provider of research and analysis on the global market for risk technology, STORM 2024 is an annual report on quantitative technologies and the computational infrastructure supporting it.
Following an extensive evaluation process, which included a risk technology survey, product demo, customer reference checks, and third-party sources of information, CRISIL won the following recognitions:
Solution category award for Model Validation Tools and AcceleratorsRanked Top 25 (#24) in QuantTech50 2024 rankingsRanked Top 25 (#24) in BuySideRisk50 2024 rankingsRanked Top 50 (#38) in RetailFinanceAnalytics50 2024 rankingsThe recognitions reflect the unparalleled value CRISIL brings to its clients through deep domain expertise, specialized analytical and technical knowledge and our global perspective.
Says Jan Larsen, President and Head, CRISIL Global Research & Risk Solutions, “CRISIL is honored by the recognition across multiple STORM50 award categories this year, including being named first place for Model Validation Tools and Accelerators. This is a great testament to the contributions of our team in giving clients and their regulators confidence in the models they use for making critical decisions.”
The core tenets of CRISIL’s value proposition include expertise across asset classes and risk stripes, analytical excellence and regulatory experience, tailored solutions focused on client delight, continuous improvement and technological innovation. 
Says Ashish Vora, President, CRISIL Market Intelligence and Analytics, “This prestigious recognition underscores the global acceptance of our risk management solutions and highlights our unwavering commitment to excellence in the risk technology space. Our Credit+ technology solutions have been instrumental in offering AI-enabled advanced analytics and driving efficiency, and we are particularly proud of the exceptional client feedback we have received for these solutions. We are constantly exploring new ways to enhance customer value and are investing in cutting-edge technology and domain expertise to maintain our position at the forefront of the industry.”
Notable examples of CRISIL’s platforms that help demonstrate this value proposition include: 
Model Infinity: A leading platform for model inventory management and model risk management. This innovative platform empowers our client to centralize all model activities, eliminates manual processes and operational risk, and provides a full audit trail of approvals for modeling assumptions and updates. Scenario Expansion Manager (SEM): A platform for clients to expand, analyze and track all regulatory and internal scenarios used for stress testing. As a centralized repository of scenarios, SEM allows institutions to eliminate redundant internal work and even provide clients the ability to share internal scenarios with one another. Credit+ ICON: The platform enables credit decision-making through its extensive financial spreading and front-end based credit risk scorecard hosting capabilities. Powered by deep domain expertise, AI-driven analytics and extensive configurability, it serves 40+ global clients across 15 countries.Credit+ Early Warning Signals: The AI-powered solution provides banks with actionable insights to monitor their credit quality, lower loan-loss contingencies and track corrective action plan.About CRISIL Market Intelligence & Analytics
About Global Research & Risk Solutions
About CRISIL Limited
Connect with us: LINKEDIN | TWITTER | YOUTUBE | FACEBOOK 
CRISIL PRIVACY
Disclaimer
This press release is transmitted to you for the sole purpose of dissemination through your newspaper/ magazine/ agency. The press release may be used by you in full or in part without changing the meaning or context thereof but with due credit to CRISIL. However, CRISIL alone has the sole right of distribution of its press releases for consideration or otherwise through any media including websites, portals, etc.
CRISIL has taken due care and caution in preparing this press release. Information has been obtained by CRISIL from sources which it considers reliable. However, CRISIL does not guarantee the accuracy, adequacy or completeness of information on which this press release is based and is not responsible for any errors or omissions or for the results obtained from the use of this press release. CRISIL, especially states that it has no financial liability whatsoever to the subscribers/ users/ transmitters/ distributors of this press release.
Logo – https://mma.prnewswire.com/media/2211784/4276223/CRISIL_logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/crisil-wins-model-validation-tools-and-accelerators-category-award-other-recognitions-from-chartis-302175882.html

Continue Reading

Trending